Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis Pauses Autoimmune Cell Therapy Studies After Deaths" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Новости GxP, European Biotechnology Magazine and Pharmaceutical Executive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 60d ago.
Quick answers
Why is "Novartis Pauses Autoimmune Cell Therapy Studies After Deaths" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- Novartis pauses eight CAR-T trials after three patient deaths Новости GxP · 62d ago
- Novartis: Three deaths put CAR-T expansion into autoimmune diseases on hold European Biotechnology Magazine · 62d ago
- Novartis and BMS Halt CAR-T Trials Pharmaceutical Executive · 62d ago
Topics
Related trends
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
SpaceX’s 80,000 Cell Site Push A Win For AST SpaceMobile, Ericsson, Nokia, NextNav, Among Others, Says Roth Capital
SpaceX's push for 80,000 cell sites creates ripple effects across the telecommunications industry, according to recent financial analysis.
SpaceX Just Made Cell Towers Cool Again. Verizon, AT&T, and T-Mobile Are Paying the Price
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Menopause: ACOG Recommends Hormone Therapy for Hot Flashes and Mood
Menopause hormone therapy receives fresh medical attention and renewed support for addressing hot flashes and mood changes.
Women ‘more likely to be told autoimmune conditions are psychological’
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Optogenetic Therapy for Restoring Aspects of Visual Function
Recent scientific findings detail the use of optogenetic therapy and special goggles to restore limited vision in blind patients.